These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 3320185)

  • 1. First clinical experience with ifoxetine, a new 5-HT reuptake blocker with particular emphasis on the side-effect profile of the 5-HT-uptake inhibiting drugs.
    Delini-Stula A; Fischbach R; Gauthier JM; Richou H; Rothweiler G; Wendt G; Wolfersdorf M
    Int Clin Psychopharmacol; 1987 Jul; 2(3):201-15. PubMed ID: 3320185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ifoxetine, a compound with atypical effects on serotonin uptake.
    Waldmeier PC; Maître L; Baumann PA; Hauser K; Bischoff S; Bittiger H; Paioni R
    Eur J Pharmacol; 1986 Oct; 130(1-2):1-10. PubMed ID: 2877890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effects of serotonin reuptake inhibitors in the treatment of depressive illness.
    Burrows GD; McIntyre IM; Judd FK; Norman TR
    J Clin Psychiatry; 1988 Aug; 49 Suppl():18-22. PubMed ID: 3045107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine. Results of dose-finding trials in depressed patients.
    Schiwy W; Heath WR; Delini-Stula A
    J Neural Transm Suppl; 1989; 28():33-44. PubMed ID: 2677240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression.
    Leinonen E; Lepola U; Koponen H; Mehtonen OP; Rimon R
    Acta Psychiatr Scand; 1997 Dec; 96(6):497-504. PubMed ID: 9421348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression.
    Davis R; Wilde MI
    CNS Drugs; 1996 May; 5(5):389-402. PubMed ID: 26071050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group.
    J Affect Disord; 1990 Apr; 18(4):289-99. PubMed ID: 2140382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin and Norepinephrine Reuptake Inhibitors.
    Shelton RC
    Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An early clinical phase II evaluation of paroxetine, a new potent and selective 5HT-uptake inhibitor in patients with depressive illness.
    Børup C; Meidahl B; Petersen IM; Vangtorp A; le Fèvre Honoré P
    Pharmacopsychiatria; 1982 Nov; 15(6):183-6. PubMed ID: 6218507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary studies with citalopram (LU 10-171), a specific 5-HT-reuptake inhibitor, as antidepressant.
    Gastpar M; Gastpar G
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(3):319-25. PubMed ID: 6959196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.
    Dechant KL; Clissold SP
    Drugs; 1991 Feb; 41(2):225-53. PubMed ID: 1709852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled cross-over study of a 5-HT uptake inhibiting and an NA uptake inhibiting antidepressant.
    Aberg A
    Acta Psychiatr Scand Suppl; 1981; 290():244-55. PubMed ID: 6452794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paroxetine in the treatment of depression--a randomized comparison with amitriptyline.
    Laursen AL; Mikkelsen PL; Rasmussen S; le Fèvre Honoré P
    Acta Psychiatr Scand; 1985 Mar; 71(3):249-55. PubMed ID: 3157296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antidepressant effects of 5-HT uptake inhibitors.
    Aberg-Wistedt A
    Br J Psychiatry Suppl; 1989 Dec; (8):32-40. PubMed ID: 2692638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Proserotoninergic agents and depression (author's transl)].
    Uzan A
    Encephale; 1982; 8(2):273-89. PubMed ID: 6286277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical overview of serotonin reuptake inhibitors.
    Rickels K; Schweizer E
    J Clin Psychiatry; 1990 Dec; 51 Suppl B():9-12. PubMed ID: 2147922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety profile of paroxetine.
    Boyer WF; Blumhardt CL
    J Clin Psychiatry; 1992 Feb; 53 Suppl():61-6. PubMed ID: 1531828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New antidepressants and 5-HT uptake inhibitors.
    Montgomery SA
    Acta Psychiatr Scand Suppl; 1989; 350():107-16. PubMed ID: 2530760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled trial of zimelidine, a 5-HT reuptake inhibitor, for treatment of depression.
    Georgotas A; Krakowski M; Gershon S
    Am J Psychiatry; 1982 Aug; 139(8):1057-8. PubMed ID: 6211994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study to establish the indication for the selective S2 antagonist ritanserin.
    Klieser E; Strauss WH
    Pharmacopsychiatry; 1988 Nov; 21(6):391-3. PubMed ID: 3149751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.